Chromogenic peptide substrate assays and their clinical applications

Griffin, 1979, Recent advances in the understanding of contact activation reactions, 5, 254 Colman, 1987, Initiation of blood coagulation at artificial surfaces, vol. 516, 253 Kaplan, 1987, The coagulation-kinin pathway of human plasma, Blood, 70, 1, 10.1182/blood.V70.1.1.1 Schmaier, 1987, Contact activation and its abnormalities, 18 Fuhrer, 1990, FXII, Blut, 61, 258, 10.1007/BF01732874 Claeson, 1979, Design of chromogenic peptide substrates, 20 Svendsen, 1979, The use of chromogenic substrates at present and in the future for factors of the coagulation, fibrinolytic and kallikrein-kinin systems, 13 Friberger, 1982, Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems, The Scandinavian Journal of Clinical and Laboratory Investigation, vol. 42 Hutton, 1987, Chromogenic substrates in haemostasis, Blood Reviews, 1, 201, 10.1016/0268-960X(87)90036-1 Zoltan, 1986, Synthetic peptide substrate assays for hemostasis testing, Advances in Clinical Chemistry, 25, 117, 10.1016/S0065-2423(08)60125-0 Blomback, 1989, Clinical application of chromogenic substrates Present and future, Clinical News (Japan), 10, 16 Hellgren, 1982, Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin, Gynecological and Obstetric Investigation, 14, 127, 10.1159/000299460 Ranby, 1982, A sensitive assay for tissue plasminogen activator, Thrombosis Research, 27, 743, 10.1016/0049-3848(82)90012-3 Wiman, 1985, A novel fast inhibitor to plasminogen activator in plasma which may be of pathophysiological significance, Scandinavian Journal of Clinical Laboratory Investigation, 45, 43 Griffin, 1981, Deficiency of protein C in congenital thrombotic disease, Journal of Clinical Investigation, 68, 1370, 10.1172/JCI110385 Bertina, 1985, Determination of plasma protein S—the protein cofactor of activated protein C, Thrombosis and Haemostasis, 53, 268, 10.1055/s-0038-1661291 Tollefsen, 1989, Heparin Cofactor II, 257 Seligsohn, 1978, Factor VII measured in amidolytic and clotting assays: A method of determining the active state of factor VII, Blood, 52, 978, 10.1182/blood.V52.5.978.978 Sandset, 1987, A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions, Thrombosis Research, 47, 389, 10.1016/0049-3848(87)90454-3 Kruithof, 1988, Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects, Fibrinolysis, 2, 59 Gallimore, 1987, A direct chromogenic peptide substrate assay for Hageman factor (FXII), Fibrinolysis, 1, 123, 10.1016/0268-9499(87)90020-8 Scott, 1984, Amidolytic assay of human factor XI in plasma: Comparison with a coagulant assay and a new rapid radioimmunoassay, Blood, 63, 42, 10.1182/blood.V63.1.42.42 Scott, 1987, A new assay for high molecular weight kininogen in human plasma using a chromogenic substrate, Thrombosis Research, 48, 685, 10.1016/0049-3848(87)90434-8 Wiman, 1983, A new simple method for determination of Cl-esterase inhibitor activity in plasma, Clinica Chimica Acta, 128, 359, 10.1016/0009-8981(83)90335-2 Kierulf, 1982, Chromogenic peptide substrate assays in patients with multiple trauma, 69 Smith-Erichsen, 1984, Evaluation of severity and prognosis in early stages of septicemia by means of chromogenic peptide substrate assays, European Surgical Research, 16, 140, 10.1159/000128633 Morrison, 1974, Direct evidence of Hageman factor (FXII) activation by bacterial lipopolysaccharides (endotoxins), Journal of Experimental Medicine, 140, 797, 10.1084/jem.140.3.797 yan Deventer, 1988, Endotoxemia: An early predictor of septicemia in febrile patients, Lancet, 1, 605, 10.1016/S0140-6736(88)91412-2 Aasen, 1978, Activities and inhibition of proteases found in plasma during endotoxin shock Gallimore, 1978, Falls in plasma levels of prekallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs, Thrombosis Research, 12, 307, 10.1016/0049-3848(78)90301-8 Aasen, 1978, Release of granulocyte elastase in lethal canine endotoxin shock, Hoppe Zeylers Zeitschrift fur Physiological Chemie, 359, 683 Jochum, 1981, Clotting and other factors in experimental endotoxemia: Inhibition of degradation by exogenous proteinase inhibitors, European Surgical Research, 13, 152, 10.1159/000128181 Aasen, 1980, Studies on components of the plasma kallikrein system in plasma samples from normal individuals and patients with septic shock, 4, 1 Schapira, 1987, Major inhibitors of the contact phase coagulation factors, 13, 69 Blauhut, 1982, Substitution therapy with an antithrombin III concentrate in shock and DIC, Thrombosis Research, 27, 271, 10.1016/0049-3848(82)90074-3 Aasen, 1985, The proenzyme functional inhibition index. A new parameter for evaluation of the severely injured and septic patient, Act Chirurgica Scandinavica, 211 Colucci, 1980, Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation, Journal of Clinical Investigation, 75, 818, 10.1172/JCI111777 Hellgren, 1984, Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients, Intensive Care Medicine, 10, 23, 10.1007/BF00258064 Velasco, 1986, Behaviour of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS), Thrombosis and Haemostasis, 55, 357, 10.1055/s-0038-1661563 Walshe, 1987, Perturbation of the kallikrein-kinin system in adult respiratory distress syndrome (ARDS), Thrombosis and Haemostasis, 58, 418 Aasen, 1989, Role of endotoxin and proteases in multiple organ failure (MOF), 308, 305 Wiman, 1986, Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay, Thrombosis and Haemostasis, 55, 189, 10.1055/s-0038-1661519 Fuhrer, 1986, Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass, 198B, 385 Egberg, 1988, Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites, Fibrinolysis, 2, 101, 10.1016/0268-9499(88)90373-6 Fuhrer, 1989, Studies on the inhibition of plasma kallikrein, Cl-esterase and β FXIIa in the presence and absence of heparins, 247B, 61 Royston, 1987, The effect of aprotinin on need for blood transfusion after repeated open-heart surgery, Lancet, 11, 1289, 10.1016/S0140-6736(87)91190-1 Jochum, 1984, An enzymatic assay convenient for the control of aprotinin levels during proteinase inhibitor therapy. Fresenius Zeitschrift 7, Analytical Chemistry, 317, 719, 10.1007/BF00593874 Gallimore, 1989, Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy, 247B, 55 Wachtfogel, 1987, Human neutrophil degranulation during extracorporeal circulation, Blood, 69, 324, 10.1182/blood.V69.1.324.324 Gallimore, 1989, The effects of plasma kallikrein and beta FXIIa (FXIIf) on blood components circulating in a cardiopulmonary bypass machine, Thrombosis and Haemostasis, 62, 268 Walker, 1981, The coagulation, fibrinolytic and plasma kallikrein systems in acute pancreatitis, 291 Aasen, 1982, Studies on pathological proteolysis in patients with acute pancreatitis. A preliminary report, 83 Lasson, 1984, Acute pancreatitis in man, Scandinavian Journal of Gastroenterology, 1 Stormorken, 1978, Chromogenic substrate assay of plasma prekallikrein, Haemostasis, 7, 69 Rodzynek, 1984, Antithrombin III, plasminogen and alpha2 antiplasmin in jaundice. Clinical usefulness and prognostic significance, Gut, 25, 1050, 10.1136/gut.25.10.1050 Cordova, 1986, Prekallikrein and factor VII as prognostic indexes of liver failure, American Journal of Clinical Pathology, 85, 579, 10.1093/ajcp/85.5.579 Lohri, 1987, Factor XII, plasma prekallikrein, α2-macroglobulin and C1-inhibitor levels in renal allograft recipients during immunosuppression with cyclosporin A—Sequential measurements over four months in 17 patients, Thrombosis and Haemostasis, 58, 993, 10.1055/s-0038-1646043 Schrader, 1988, Parameters of the kallikrein-kinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection, Nephron, 48, 183, 10.1159/000184909 Schrader, 1989, Results of antithrombin III treatment in patients after kidney transplantation, Nephron, 52, 192, 10.1159/000185634 Mannhalter, 1985, Clotting activities and antigen concentrations of contact factors in kidney disease, Thrombosis Research, 39, 475, 10.1016/0049-3848(85)90171-9 Schrader, 1989, Antithrombin III in renal disease, 43 Coacute Antithrombin and Coacute Heparin. KabiDiagnostica, Taljegardsgatan 3, S-431 53 Molndal, Sweden Margolis, 1971, Altered kallikrein excretion in human hypertension, Lancet, 11, 1063, 10.1016/S0140-6736(71)90382-5 Overlack, 1980, Decreased urinary kallikrein activity and elevated blood pressure normalised by orally applied kallikrein in essential hypertension, Klinische Wochenschrift, 58, 37, 10.1007/BF01477142 Campbell, 1989 Bruhn, 1982, Plasma prekallikrein in hypertension, 133 Derkx, 1979, An intrinsic factor XII-prekallikrein-dependent pathway activates the human plasma renin-angiotensin system, Nature, 280, 315, 10.1038/280315a0 Ole-Moiyoi, 1979, Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kinase, 76, 3612 Uehara, 1988, Kallikrein-kinin system in diabetic patients, Arzneimer Forschung/Drug Research, 38, 721 O'Meara, 1958, Coagulative properties of cancer, Irish Journal of Medical Science, 394, 474, 10.1007/BF02950524 Wada, 1982, Coagulant and fibrinolytic activities in the leukemic cell lysates, Thrombosis Research, 30, 315, 10.1016/0049-3848(83)90223-2 Latallo, 1979, A new approach to study factors from tumour cells which influence the clotting and fibrinolytic systems, IV, 411 Gallimore, 1981, Further studies on components of the plasma kallikrein system in plasma samples from cancer patients and normal individuals, V, 256 Osther, 1974, C1 inactivator from cancer cells, Lancet, 2, 359, 10.1016/S0140-6736(74)93117-1 Werk, 1981, Plasma kallikrein activities, FDP and Cl-esterase inhibitor levels in breast cancer patients, V, 259 De Jong, 1987, Increased plasminogen activator inhibition levels in malignancy, Thrombosis and Haemostasis, 57, 140, 10.1055/s-0038-1651082 Donaldson, 1963, A biochemical abnormality in heriditary angioedema: absence of serum inhibitor of C1-esterase, American Journal of Medicine, 35, 37, 10.1016/0002-9343(63)90162-1 Cullman, 1982, Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE), Clinical and Experimental Immunology, 49, 618 Gallimore, 1983, Studies on components of the plasma kallikrein and complement systems in plasma and serum samples from normal individuals and patients with hereditary angioedema, 156B, 1099 Schapira, 1983, Prekallikrein activation and high molecular weight kininogen consumption in hereditary angio-edema, New England Journal of Medicine, 308, 1050, 10.1056/NEJM198305053081802 Kaplan, 1976, In vitro studies of the pathogenesis of cold urticaria, cholinergic urticaria and vibration-induced swelling, Journal of Investigative Dermatology, 67, 327, 10.1111/1523-1747.ep12514352 Nilsson, 1984, On the role of the Cl-esterase inhibitor in cold urticaria, Acta Dermatologica Venerologica, 64, 197 Stockley, 1983, Proteolytic enzymes, their inhibitors and lung diseases, Clinical Science, 64, 119, 10.1042/cs0640119 Beatty, 1982, Determination of oxidised alpha-l-proteinase inhibitor in serum, Journal of Laboratory and Clinical Medicine, 100, 186 van Deventer, 1987, Clinical evaluation in febrile patients of an optimised endotoxin assay in blood, 489 Friberger P In Press Endotoxin determinations with limulus lysate in clinical diagnosis and hygenic control. In: Gupta A P (ed) Immunology of insects and other arthropods. CRC Press, Florida Alving, 1978, Hypotension associated with pre-kallikrein activator (Hageman factor fragments) in plasma protein fraction, New England Journal of Medicine, 299, 66, 10.1056/NEJM197807132990203 Alving B M, Tankersley D L, Mason B L, Rossi F, Aronson D L, Finlayson J S. Contact activated factors: contaminants of immunoglobulin preparations coagulant and vasoactive properties. Journal of Laboratory and Clinical Medicine 96: 334–346 Abildgaard, 1989, Monitoring heparin treatment, 495 Holmer, 1989, Low molecular weight heparin, 575